The use of essential medicines has been upgraded!

The National Health and Medical Commission's Medical Administration and Hospital Administration recently issued the "Notice on Printing and Distributing the Performance Assessment Operation Manual of National Secondary Public Hospitals (2022 Edition)", and conducted a review of the "National Secondary Public Hospitals Performance Assessment Operation Manual (2020 Revised Edition.

Industry insiders pointed out that the policy requirements for the use of purchased varieties of essential medicines have been put forward in the performance appraisal of national tertiary public hospita.

Second-level hospitals usher in the "national examination"

The use of essential medicines will meet high demands again

The performance evaluation of public hospitals has always been called "national examination", so the "operation manual" can be called "pre-examination instruction.

According to the new version of the "Operation Manual", the performance evaluation index system of second-level public hospitals includes 4 first-level indicators, 10 second-level indicators, and 28 third-level indicators (all quantitative indicators), including 21 national monitoring indicato.

One of the highlights of this revision is that the content related to the procurement of essential medicines has been updat.

The "Opinions of the General Office of the State Council on Improving the National Essential Drug System" previously clearly required that public hospitals should give priority to the use of national essential drugs in an all-round way, adhere to the dominant position of essential drugs, strengthen the management of the use of essential drugs in medical institutions, and clarify public medical care on a provincial bas.

According to the new version of the "Operation Manual" released this time, the calculation method for the proportion of the purchase amount of essential medicines is: the proportion of the amount of essential medicines purchased by the hospital in the assessment year to the total amount of medicines purchased by the hospital in the same peri.

In addition, as mentioned above, the new version of the "Operation Manual" released this time has added a number of extended indicators:

"Strengthening the grassroots level" and "hierarchical diagnosis and treatment" have been the key words of China's medical reform over the years, but it is undeniable that the development of China's medical resources is still very unev.

Previously, the managers of primary medical institutions once said that there are many reasons that make it difficult for primary medical services to fully meet the needs of the peop.

At present, the Essential Medicines List has been revised twice, and the total number of medicines in the list has increased from 307 to the current 68 The varieties are constantly expandi.

In order to better meet the needs of the public for medication, on October 11, 2019, the General Office of the State Council issued the "Opinions on Further Ensuring Supply and Price Stabilization of Shortaged Drugs", which clarified the data on the proportion of essential drugs used at the national lev.

After the implementation of the baton of the hospital performance evaluation of the second-level public hospitals, the proportion of the number of basic drugs purchased and the proportion of basic drug prescriptions used by outpatient and inpatient patients have become new assessment standards, which will further force medical institutions to increase the number of basic dru.

It is believed that with the adjustment and implementation of the new version of the essential medicine list and the in-depth advancement of the "986 policy" and the "1+X" medication model, the grassroots market and essential medicines will receive more attention, and essential medicines may become a new market competition point in the futu.

The grassroots market is no longer "cheap"

The new version of the list of essential medicines has more than 1,000 varieties?

The goal of China's new medical reform is very clear: to solve the difficult and expensive medical treatme.

The second-level hospitals face the grassroots and rural areas, are in the first line of medical care, and occupy a large proportion in China's medical and health syst.

In fact, since the implementation of the essential medicine system, the list has been dynamically adjusted every three years in principle, and due to the impact of the new crown pneumonia epidemic, the revision of the new version of the list has always attracted the attention of the indust.

Since 2021, the news of the adjustment of the list of essential medicines has continu.

The 2021 National Drug Administration Work Conference made it clear that one of the key tasks is to fully promote the implementation of the essential drug system and optimize and adjust the national essential drug li.

In November 2021, the National Health and Medical Commission publicly solicited opinions from the whole society to adjust the essential drug list and clarify the scope of drug selecti.

It is generally believed in the industry that the national essential drug list will be officially adjusted in 202

In fact, since the establishment of the National Medical Insurance Administration, with the in-depth progress of volume procurement and medical insurance negotiation, the positioning and role of the Essential Drug List seems to be being dilut.

Market participants pointed out that the drugs included in the traditional essential medicine list are usually commonly used drugs and generic drugs, and the prices are generally relatively l.

Therefore, for a period of time, pharmaceutical companies have not been very enthusiastic about entering innovative varieties into the li.

However, at the "two sessions" this year, Yao Shukun, a member of the National Committee of the Chinese People's Political Consultative Conference and former vice president of the China-Japan Hospital, submitted a proposal to "guarantee the local production and supply of essential medicines and improve the accessibility of patient.

He suggested that the prices of essential medicines that are too low should be appropriately raised, and reasonable profits should be set aside for production enterprises, so as to avoid the disappearance of high-quality, cheap and irreplaceable "life-saving medicines" at the grassroots lev.

It is not unheard of for it to "disappear" after entering the list of essential medicin.

After the breast cancer drug "Herceptin" and the hematological tumor-based chemotherapy drug "Sedsa", two commonly used clinical drugs entered the list of essential drugs, there were clinical supply problems in 2018 and 2019 respective.

According to anecdotal reports, it is expected that about 270 new varieties will be added to the list of essential medicines, which may cover 130 varieties of chemical drugs and 140 varieties of Chinese patent medicin.

If the information is accurate, the list of essential medicines may burst to the order of thousan.

According to industry insiders, the list of essential medicines may be adjusted in several directions: one is to supplement Chinese patent medicin.

In recent years, the Chinese medicine market has continued to “warm up”, and there is a strong voice for the return of the value of traditional Chinese medicines in the post-epidemic era; the other is to supplement the clinical effe.

, drugs with fewer side effects; third, drugs that are clinically necessary, have good effects, and high drug prices, especially high-value innovative drugs whose prices have been greatly reduced in volume purchases and price negotiations; fourth, large clinical doses and high recogniti.

Drugs for chronic diseases; Fifth, medicines for childr.

"It is not impossible for innovative drugs to enter basic dru.

The key is clinical value and whether they can meet clinical nee.

Taking the revision of the basic drug list in 2018 as an example, 12 new cancer drugs that are urgently needed in clinic have been included, and new hepatitis C drugs have also been adjusted to basic dru.

in the drug catal.

"

For the grass-roots market, entering the essential drug list means obtaining an "entry ticket" to the county-level market, especially in the hospital admission process, which is bound to increase the success of products entering the hospit.

For multinational pharmaceutical companies, it is undoubtedly quite attracti.